Effect of dapagliflozin on the no-reflow phenomenon in patients with acute myocardial infarction and type II diabetes mellitus
Lower rates of the no-reflow phenomenon were observed in T2DM patients taking dapagliflozin, diagnosed with AMI, and underwent PCI. However, this finding requires further investigation.
Authors
- Gökhan Alıcı (ORCID: https://orcid.org/0000-0002-4589-7566)
- Alaa Quisi (ORCID: https://orcid.org/0000-0002-5862-5789)
- Ömer Genç (ORCID: https://orcid.org/0000-0002-9097-5391)
- Abdullah Yıldırım (ORCID: https://orcid.org/0000-0002-7071-8099)
- Nur Selin Nacar Quisi
- İdil Donma
Institutions
- Yang Hospital (KR)
- Medline (United States) (US)
- İstanbul Başakşehir Çam ve Sakura Şehir Hastanesi
- Cukurova University (TR)
Publication Details
- Journal
- Acta cardiologica. Supplementum
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1080/00015385.2025.2500892
- Citations
- 9
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 11.65